trending Market Intelligence /marketintelligence/en/news-insights/trending/es-s7ndbw2bnds2iezxlba2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Gene editing execs talk CRISPR potential; 2018 healthcare IPOs top 2017 proceeds

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Gene editing execs talk CRISPR potential; 2018 healthcare IPOs top 2017 proceeds

Here are the editors' top picks for the week ended Oct. 12.

A CRISPR primer: Gene editing company leaders talk tech's potential in humans

What's all the fuss about with Clustered Regularly Interspaced Short Palindromic Repeats? The major CRISPR companies' executives explain how the tool works and what it is being leveraged for ahead of the first company-sponsored human trial.

Global healthcare IPOs fetch $19.18B year-to-date, topping 2017 proceeds

Gross proceeds from global healthcare IPOs year-to-date in 2018 exceeded amounts raised last year, according to data compiled by S&P Global Market Intelligence.

New study links IVF process itself to higher chance of multiple births

The largest study ever of multiple pregnancies after a single embryo transfer during IVF has found that using thawed embryos or maturing the fertilized egg in the laboratory before implanting it could increase the risk of multiple births.

Healthcare equipment companies drive M&A activity in Q3

Deals for healthcare equipment companies largely drove M&A activity in the third quarter as companies shored up their core business with acquisitions.

Trevena opioid oliceridine rejected by US FDA panel in close vote

An outside panel of expert advisers to the U.S. Food and Drug Administration declined to recommend approval of Trevena Inc.'s intravenous opioid oliceridine, narrowly voting it down 8 to 7.

AbbVie, Novartis settle Humira biosimilar dispute for 2023 US launch

AbbVie Inc. has agreed to grant Novartis AG generic unit Sandoz a license to market a biosimilar of rheumatoid arthritis drug Humira beginning in 2023, marking an end to a patent lawsuit between the two pharmaceutical companies.

Medtronic disables internet updates for 2 medical devices over hacking concerns

Medtronic plc disabled internet updates on Oct. 11 for two CareLink models after warning doctors about the devices' vulnerability to cyberattacks. The company said there have been no reports of patients being harmed from a cyberattack.

Canadian regulators call for more transparent disclosure from cannabis companies

Just in time for Canada's legalization of marijuana, the Canadian Securities Administrators have asked cannabis companies to improve disclosure processes after a review of 70 companies revealed practices that would not properly inform investors.

Amgen vs. Novartis: Enbrel patent fight will further shape biosimilar law

A biosimilar law fraught with ambiguities will once again be shaped by a fight between Amgen Inc. and Novartis over the autoimmune drug Enbrel.

China adds 17 anti-cancer drugs under national insurance coverage

The State Medical Insurance Administration said in a notice on its website that provincial regulators will come up with detailed rules regarding reimbursement of the drugs.

Novo Nordisk shares slide as competition intensifies in diabetes, hemophilia

Shares in Novo Nordisk A/S continued to slide as investors digested news that Roche Holding AG's rival hemophilia drug Hemlibra received expanded approval on the same day that Eli Lilly and Co. released positive data for its experimental diabetes medicine.

Capitol Checkup: Pro-pharma group revealed; GOP 'pre-existing conditions' zeal

A new pro-brand-name drug industry group revealed who was running the organization, but details about its funding remain unclear; and after years of trying to repeal the Affordable Care Act, some Republicans are now backtracking ahead of elections.